Clareo Health | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ocular Therapeutix, Inc.
Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (axitinib implant) for Intravitreal Injection in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are at least 18 years of age or older
Moderately severe to severe NPDR in the study eye defined as: DRSS levels of 47 or 53 as determined by the reading center
Diabetes type 1 or 2
BCVA ETDRS letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)
You may not be if
DME within 6 months involving the center of the macula in the study eye
Presence of DME threatening the center (within 200 microns) of the macula in the study eye
